Pfizer Wins Promotion Contract Row In Pa. Appeals Court

Law360, New York (March 26, 2013, 1:42 PM EDT) -- A Pennsylvania appeals court found Monday that Pfizer Inc. is entitled to an extension in a multiple sclerosis drug promotion agreement it inked with EMD Serono Inc., saying the agreement is valid even though the drug's U.S. Food and Drug Administration approval fell through.

The Pennsylvania Superior Court found that Pfizer's decision to jointly promote EMD Serono's cladribine drug extended the terms of a pre-existing co-promotion agreement between the companies and rejected EMD Serono's argument that the extension applied only if the FDA approved its drug...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.